Abstract 4P
Background
Complications of immediate breast reconstruction caused by chemotherapy or radiotherapy have been debated, but these complications may delay the end of adjuvant treatment and subsequently increase the recurrence. The purpose of this study was to identify risk factors of tissue expander or implant removal and difference of duration from mastectomy to tissue expander or implant removal.
Methods
We conducted a retrospective study of total 11362 breast cancer patients between 2012 and 2017 who were identified in Samsung Medical Center. Eligible patients were total 1091 female breast cancer patients after nipple sparing mastectomy or skin sparing mastectomy with tissue expander or direct implant insertion.
Results
602 (55.2%) patients (group A) have not chemotherapy (CTx), 61 (5.6%) patients (group B) have neoadjuvant CTx and 428 (39.2%) patients (group C) have adjuvant CTx. 897 (82.2%) patients (group D) have not radiotherapy (RTx), 194 (17.8%) patients (group E) have RTx. 1050 (96.2%) patients (group N) have not tissue expander or implant removal and 41 (3.8%) patients (group R) have tissue expander or implant removal. Baseline and pathologic characteristics of patients were not different except N stage between group N and group R. Univariate analysis showed increased pathologic N stage was significantly associated tissue expander or implant removal. (HR = 14.769, 95% CI = 4.338 to 50.284). Tissue expander or implant removal occurred more group B (6.6%) than group A (2.0%) (HR = 3.450, 95% CI = 1.078 to 11.048), more group C (5.8%) than group A (HR = 3.050, 95% CI = 1.515 to 6.141) and more group E (8.8%) than group D (2.7%) (HR = 3.494, 95% CI = 1.839 to 6.639). In multivariate analysis, N stage decreases, tissue expander or implant removal occurred earlier (P < .05). Median time of duration from operation to tissue expander or implant removal was 495 days (range 10-2423 days).
Conclusions
Immediate reconstruction with tissue expander or implant after mastectomy may be a choice of treatment option even in breast cancer patients who will be received chemotherapy or radiotherapy. These results will aid preoperative counselling to patients who are concerned about complication of immediate reconstruction caused by chemotherapy or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract